Overview
WuXi AppTec
Drug makers with a need to outsource technical services turn to WuXi PharmaTech. The company provides laboratory and manufacturing services for customers in the pharmaceutical, biotechnology, and medical equipment industries. Its core lab services business offers contract research, discovery chemistry, service biology, device testing, and pharmaceutical development services. WuXi's ancillary manufacturing operations mainly produce advanced intermediate
...
Read More drugs, biologics-based drugs, and active drug ingredients. Top customers include leading global drug makers Pfizer and Merck.
Read Less
Read More drugs, biologics-based drugs, and active drug ingredients. Top customers include leading global drug makers Pfizer and Merck.
Read Less
Ge Li
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Medical research, commercial
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$5.42 billion
Actual
-2.73%
-1.63%
$80,325
DEC
?
?
Shanghai:603259
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$5.42 billion
USD
Actual
1 USD = 7.2455 CNY
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $1,712 | $1,848 | $1,465 |
| Net Investing Cash | -$762 | -$1,043 | -$1,337 |
| Net Financing Cash | -$529 | -$544 | -$176 |
| Net Change in Cash | $422 | $260 | -$49 |
| Cash at Beginning of Period | $1,380 | $1,102 | $1,128 |
| Cash at End of Period | $1,856 | $1,380 | $1,102 |
| Capital Expenditure | -$553 | -$761 | -$1,375 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $2,529 | $1,900 | $1,102 |
| Accounts Receivable | $1,097 | $1,091 | $824 |
| Inventories | $745 | $654 | $782 |
| Other Current Assets | $968 | $555 | $603 |
| Asset Summary | |||
| Total Current Assets | $5,340 | $4,199 | $3,312 |
| Tangible Fixed Assets | $3,540 | $3,528 | $3,125 |
| Intangible Assets | $217 | $257 | $246 |
| Total Assets | $80,326 | $73,669 | $64,690 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $244 | $227 | $229 |
| Short-Term Debt | $172 | $506 | $535 |
| Other Current Liabilities | $1,824 | $1,303 | $1,237 |
| Liability Summary | |||
| Total Current Liabilities | $2,239 | $2,037 | $2,001 |
| Long-Term Debt | $408 | $95 | $108 |
| Other Long-Term Liabilities | $ | $ | $20 |
| Total Liabilities | $2,932 | $2,505 | $2,452 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $399 | $410 | $409 |
| Retained Earnings | $4,418 | $3,557 | $2,641 |
| Equity Summary | |||
| Total Equity | $8,092 | $7,608 | $6,430 |
| Shares Outstanding | 2,887,992,582 | 2,968,844,903 | 2,960,526,697 |